

REMARKS

Claims 1- 32 are presented in this application. Claims 3, 5, 7-10, 12-14, 16, 18, 20, 22, 23 and 25-29 have been amended to place them in form appropriate to US practice and to remove multiple dependencies for the purpose of reducing fees. None of these amendments are made in view of the Prior art. Claim 33 has been canceled. Applicants reserve the right to prosecute the subject matter of this claim in the future.

Applicants have amended the specification for purposes of adding the priority information. Applicants have attached an Abstract on a separate sheet of paper as required by US practice.

Entry of the amendment prior to the examination of the application and calculation of the filing fee is respectfully requested.

The Commissioner is hereby authorized in this, concurrent, and future replies, to charge any fees or credit any overpayment, particularly including any fees required under 37 CFR Sect 1.16 or 1.17, and any necessary extension of time fees, to deposit Account No. 07-1392.

Respectfully submitted,



Robert J. Smith  
Attorney for Applicant  
Registration No. 40,820

Date: October 12, 2005  
GlaxoSmithKline  
Corporate Intellectual Property  
Five Moore Drive  
P.O. Box 13398  
Research Triangle Park, NC 27709-3398  
Phone: 919-483-9616  
Facsimile: 919-483-7988